Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Other Operating Expenses (2018 - 2025)

Marker Therapeutics (MRKR) has disclosed Other Operating Expenses for 3 consecutive years, with -$1.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$1.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $453134.0, a N/A change, with the full-year FY2018 number at $116.0 million, changed N/A from a year prior.
  • Other Operating Expenses was -$1.0 for Q3 2025 at Marker Therapeutics, down from $453135.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $11.5 million in Q3 2022 to a low of -$1.0 in Q3 2025.